Cite
Diels J, Angermund R, Schroeder M, et al. The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM). Value Health. 2014;17(7):A334doi: 10.1016/j.jval.2014.08.639.
Diels, J., Angermund, R., Schroeder, M., Worbes-Cerezo, M., & Thompson, G. (2014). The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM). Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A334. https://doi.org/10.1016/j.jval.2014.08.639
Diels, J, et al. "The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM)." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A334. doi: https://doi.org/10.1016/j.jval.2014.08.639
Diels J, Angermund R, Schroeder M, Worbes-Cerezo M, Thompson G. The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM). Value Health. 2014 Nov;17(7):A334. doi: 10.1016/j.jval.2014.08.639. Epub 2014 Oct 26. PMID: 27200590.
Copy
Download .nbib
